<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120939</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0212</org_study_id>
    <nct_id>NCT00120939</nct_id>
  </id_info>
  <brief_title>Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer</brief_title>
  <official_title>Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, side effects, and dosage for
      Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced
      cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and
      drug interactions will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin Gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Metastatic, or unresectable solid tumors from breast, head, and neck,
             gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma
             multiforme

          -  ECOG performance status score either 0, 1, or 2

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Greater than two prior cytotoxic regimens

          -  Laboratory values showing adequate function of bone marrow, liver, and kidneys

          -  Uncontrolled hypertension

          -  Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel,
             docetaxel) or polysorbate 80
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurkamal Chatta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2005</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Genitourinary Cancer</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Recurrent Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Throat Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Renal Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

